More than half of drug launches fall short of forecasts. Engaging payers during trial design and capturing outcomes with real ...

The number of employees laid off and companies letting people go increased year over year during the first half of 2025.

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Biogen, with a price target of $224.00. The company’s shares closed yesterday at $130.13. Do ...

After the FDA rejection of Zurzuvae in one type of depression and the triple failure of neuro asset dalzanemdor, Sage was searching for a path forward at the end of December 2024. Biogen CEO Chris ...

BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.

FN Media Group News Commentary - Worldwide, there is a rising demand for neuropsychiatric disorder treatments which is expected to fuel the global markets for years to come. With expanding research ...

The trial between Genentech Inc. and Biogen MA Inc. officially opened Monday in the U.S. District Court for the Northern District of California, centering on a $122 million royalties dispute related ...

Biogen on Monday said the phase 3 study will evaluate the efficacy and safety of felzartamab compared to the immunosuppressive drug tacrolimus in adults with PMN, with a readout expected in 2029.

Two weeks after Supernus unveiled the Sage Therapeutics acquisition, all 338 employees from the struggling biotech are being laid off.

Cambridge biotech firm Sage Therapeutics is laying off most of its employees after announcing its planned acquisition earlier this month. Sage will cut 338 jobs effective Aug. 22, according to ...